Physician profile
Steven M Taback
NPI 1225004021
$2,329.67
in general payments reported to CMS, 2019-2025
13 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $58.89 · 2021: $23.12 · 2022: $33.16 · 2023: $1,586 · 2024: $236 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $990 · Food and Beverage: $772 · Gift: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $990.11 |
| Food and Beverage | $772.35 |
| Gift | $330.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,527.35 | 2023 | Da Vinci Surgical System |
| Stryker Corporation | $216.75 | 2024-2025 | Prevalon |
| Glaxosmithkline, LLC. | $192.05 | 2019-2025 | Nucala, Trelegy Ellipta |
| Medtronic, INC. | $99.63 | 2025 | Absorbatack |
| Philips North America LLC | $73.50 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $62.28 | 2024 | Optimizer |
| Pulmonx Corporation | $33.16 | 2022 | |
| Amgen INC. | $24.92 | 2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $23.12 | 2021 | |
| Allergan, INC. | $22.61 | 2020 | |
| Insmed, INC. | $20.24 | 2024 | Arikayce |
| Janssen Pharmaceuticals, INC | $17.34 | 2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $16.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Taback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.